Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Overcoming resistance to targeted anticancer drugs.

Doroshow JH.

N Engl J Med. 2013 Nov 7;369(19):1852-3. doi: 10.1056/NEJMe1311325. Epub 2013 Nov 1. No abstract available.

PMID:
24180495
2.

Ponatinib in Philadelphia chromosome-positive leukemias.

Quintas-Cardama A.

N Engl J Med. 2014 Feb 6;370(6):577. doi: 10.1056/NEJMc1315234#SA1. No abstract available.

PMID:
24499222
3.

Ponatinib in Philadelphia chromosome-positive leukemias.

Cortes JE, Talpaz M, Kantarjian H.

N Engl J Med. 2014 Feb 6;370(6):577. doi: 10.1056/NEJMc1315234. No abstract available.

4.

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Narayanan V, Pollyea DA, Gutman JA, Jimeno A.

Drugs Today (Barc). 2013 Apr;49(4):261-9. doi: 10.1358/dot.2013.49.4.1950147. Review.

PMID:
23616953
5.

Complicated and Advanced Atherosclerosis in a Young Woman With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Success and Challenges of BCR/ABL1-Targeted Cancer Therapy.

Herrmann J, Bell MR, Warren RL, Lerman A, Fleming MD, Patnaik M.

Mayo Clin Proc. 2015 Aug;90(8):1167-8. doi: 10.1016/j.mayocp.2015.05.013. No abstract available.

PMID:
26250733
6.

[Chronic myeloid leukemia].

Tojo A.

Nihon Rinsho. 2012 Nov;70 Suppl 8:501-7. Japanese. No abstract available.

PMID:
23513891
8.

Ponatinib (Iclusig) for CML and Ph+ ALL.

[No authors listed]

Med Lett Drugs Ther. 2013 Sep 2;55(1424):71-2. Review. No abstract available.

PMID:
25970013
9.

Ponatinib for chronic myeloid leukemia.

Goldman JM.

N Engl J Med. 2012 Nov 29;367(22):2148-9. doi: 10.1056/NEJMe1210796. No abstract available.

PMID:
23190226
10.

Cancer-drug discovery and cardiovascular surveillance.

Groarke JD, Cheng S, Moslehi J.

N Engl J Med. 2013 Nov 7;369(19):1779-81. doi: 10.1056/NEJMp1313140. Epub 2013 Nov 1. No abstract available.

PMID:
24180496
11.

Circumventing resistance to kinase-inhibitor therapy.

Druker BJ.

N Engl J Med. 2006 Jun 15;354(24):2594-6. No abstract available.

PMID:
16775240
12.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

Klyuchnikov E, Schafhausen P, Kröger N, Brummendorf TH, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuk F, Zander AR, Bacher U.

Acta Haematol. 2009;122(1):6-10. doi: 10.1159/000228587. Epub 2009 Jul 15. No abstract available.

PMID:
19602874
13.

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F.

Expert Rev Anticancer Ther. 2015 Apr;15(4):365-73. doi: 10.1586/14737140.2015.1025256. Epub 2015 Mar 12. Review.

PMID:
25764322
14.

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.

Shomali W, Redmond C, Bogati S, Zimmerman C, Visconte V, Tabarroki A, Kalaycio M, Tiu RV.

Leuk Lymphoma. 2016;57(1):193-5. doi: 10.3109/10428194.2015.1036259. Epub 2015 Jun 18. No abstract available.

PMID:
25942382
15.

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F.

J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15. No abstract available.

PMID:
19075254
16.

Dasatinib (Sprycel) for CML and Ph + ALL.

[No authors listed]

Med Lett Drugs Ther. 2007 Jan 15;49(1252):6-7. No abstract available.

PMID:
17220814
17.

Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?

Thomas X.

Lancet Oncol. 2015 Nov;16(15):1451-3. doi: 10.1016/S1470-2045(15)00247-8. Epub 2015 Sep 30. No abstract available.

PMID:
26432047
18.

Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.

Hu T, Ciccarelli BT.

Leuk Res. 2014 Dec;38(12):1399-400. doi: 10.1016/j.leukres.2014.09.015. Epub 2014 Oct 16. No abstract available.

PMID:
25449686
19.

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ.

Blood. 2007 Jan 15;109(2):500-2. Epub 2006 Sep 21.

20.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M.

J Clin Oncol. 2006 Nov 20;24(33):e51-2. No abstract available.

PMID:
17114651

Supplemental Content

Support Center